Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Somewhat Bullish +50

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX)

📈 TD Cowen analyst Mathew Blackman maintains a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $109.00, up from the company's closing price of $87.80 last Monday.

👤 Analyst Blackman holds a 4-star rating with a 44.8% success rate and covers Healthcare stocks including Tandem Diabetes Care and Intuitive Surgical.

📊 The current analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $109.00, though the consensus target mentioned in the text as $100.38 suggests a Buy rating divergence.

💰 Alliance Global Partners analyst Brian Kinstlinger maintained a Buy rating on 20/20 Biolabs, Inc. (AIDX) and set a price target of C$2.25.

📉 20/20 Biolabs, Inc. shares closed last Monday at $1.99, trading close to its 52-week low of $1.70 and below the analyst consensus target of $1.82.

⭐ Analyst Brian Kinstlinger is a 5-star analyst with an average return of 10.2% and covers Technology sector stocks.

🏥 Stifel Nicolaus also maintained a Buy rating on 20/20 Biolabs, Inc. in a report issued on March 11 with a higher C$3.10 price target.

⚖️ The analyst consensus for 20/20 Biolabs, Inc. is Moderate Buy based on the combined positive sentiments from multiple firms.

🔍 TipRanks aggregates hedge fund-level data and provides insights on healthcare stocks like ZBH and AIDX through paid content partnerships.

⚠️ The article contains syndicated third-party press releases that have not been reviewed or endorsed by The Globe and Mail.

📝 Additional headlines link Zimmer Biomet to studies on knee implants, ROSA knee pilot studies, and recent downgrades to Neutral at BTIG.

Bullish Signals
  • TD Cowen analyst Mathew Blackman maintained a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $109.00, which represents upside potential from the recent closing price of $87.80.
  • Analyst Mathew Blackman boasts an impressive 44.8% success rate and an average return of 9.1%, providing confidence in his bullish sentiment on ZBH.
  • 20/20 Biolabs, Inc. (AIDX) received a Buy rating from Alliance Global Partners analyst Brian Kinstlinger with a price target of C$2.25, showing upside potential above the recent closing price of $1.99.
  • Analyst Brian Kinstlinger is recognized as a 5-star analyst on TipRanks.com with an average return of 10.2%, indicating strong track record and credibility.
  • Despite current consensus suggesting moderate downside for 20/20 Biolabs, Stifel Nicolaus maintained a Buy rating with a C$3.10 price target as recently as March 11, signaling continued institutional optimism.
  • The market presence of multiple analysts maintaining Buy ratings on both ZBH and AIDX indicates growing sector-wide confidence in healthcare investment opportunities.
Risk Factors
  • Zimmer Biomet Holdings (ZBH) has a Hold consensus rating among analysts with an average price target of $109.00, while individual analyst price targets are split between Buy ($109.00) and Neutral ratings.
  • 20/20 Biolabs, Inc. (AIDX) carries a downside risk of -12.5% from its current levels based on the analyst consensus price target of $1.82 versus the closing share price of C$1.99.
  • The stock coverage for Zimmer Biomet is mixed, with analysts like Mathew Blackman maintaining Buy ratings while others have downgraded the stock to Neutral or Hold status recently.
  • Analyst Brian Kinstlinger covers the Technology sector primarily, including Gorilla Technology Group Inc. and Bitdeer Technologies, rather than focusing exclusively on medical device companies like Zimmer Biomet.
Full Analysis
Analysts have provided recent insights on healthcare companies Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX), maintaining bullish sentiments toward both stocks. TD Cowen analyst Mathew Blackman reiterated a Buy rating on Zimmer Biomet Holdings with a price target of $109.00, compared to the stock's Monday closing price of $87.80. Blackman is rated as a 4-star analyst with a 44.8% success rate and an average return of 9.1%. While Blackman remains positive, the overall consensus on Zimmer Biomet Holdings stands at a Hold with an average price target of $100.38, indicating some divergence among analysts covering the Healthcare sector. Conversely, Alliance Global Partners analyst Brian Kinstlinger issued a Buy rating on 20/20 Biolabs, Inc., setting a price target of C$2.25 against Monday's closing price of $1.99 and near its 52-week low of $1.70. Kinstlinger is a 5-star analyst with an average return of 10.2% and a 43.8% success rate, though he primarily covers the Technology sector including Gorilla Technology Group Inc. and Bitdeer Technologies. The current analyst consensus for 20/20 Biolabs, Inc. is Moderate Buy with an average price target of $1.82, representing a 12.5% downside from current levels. Additionally, a separate report from March 11 by Stifel Nicolaus maintained a Buy rating with a C$3.10 price target. The coverage highlights the varying analyst ratings and price targets across these companies, suggesting mixed market expectations despite individual bullish recommendations.